Related Experiment Video
Updated: Dec 25, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
Nalan Akgul Babacan1, Zeynep Eroglu2,3
1Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, USA.
Purpose Of Review:
While anti-PD-1 antibodies have been a breakthrough in the treatment of patients with advanced melanoma, a substantial proportion of patients are still refractory to or progress after treatment with anti-PD-1 immunotherapy. Here, we review the post anti-PD-1 therapy alternatives that may be possible for patients with unresectable or metastatic stage 3 or 4 melanoma.
Recent Findings:
Currently available treatment options include BRAF-targeted and MEK inhibitor-targeted therapies for those with BRAFV600 mutant melanoma, while for patients with BRAF-WT melanoma or those who have already received prior BRAF-targeted therapy, options include anti-CTLA-4 therapy, alone or in combination with anti-PD-1 therapy, or for selected patients, clinical trials that may incorporate other immune checkpoint inhibitors or co-stimulatory agonists, oncolytic virotherapies, adoptive cellular therapies, or other novel agents. Participation in clinical trials is critical in order to delineate what more effective treatment options are and which group of patients after receiving prior anti-PD-1 therapy.
Insights
For advanced melanoma patients resistant to anti-PD-1 therapy, alternative treatments like BRAF/MEK inhibitors or other immunotherapies are available. Clinical trials offer novel options for unresectable or metastatic melanoma.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Anti-PD-1 antibodies represent a significant advancement in treating advanced melanoma.
- However, a notable percentage of patients exhibit resistance or disease progression following anti-PD-1 immunotherapy.
Purpose of the Study:
- To review and outline alternative therapeutic strategies for patients with unresectable or metastatic (Stage 3 or 4) melanoma who have progressed on or are refractory to anti-PD-1 therapy.
Main Methods:
- Literature review of current and emerging treatment modalities.
- Analysis of therapeutic options based on BRAF mutation status and prior treatment history.
Main Results:
- For BRAFV600 mutant melanoma, BRAF-targeted and MEK inhibitor therapies are options.
- For BRAF-wildtype melanoma or post-BRAF-targeted therapy, options include anti-CTLA-4 therapy (alone or with anti-PD-1), and enrollment in clinical trials.
- Clinical trials may involve novel immune checkpoint inhibitors, co-stimulatory agonists, oncolytic virotherapies, adoptive cellular therapies, or other innovative agents.
Conclusions:
- A range of post-anti-PD-1 therapy alternatives exist for advanced melanoma.
- Clinical trial participation is crucial for identifying optimal future treatments and patient populations for these advanced therapies.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...